Comparison of cognitive and neuropsychological manifestations in patients with progressive supranuclear palsy (Psp) and Parkinson’s disease
Objective: 1) To compare the cognitive and neuropsychological manifestations between the patients with PSP and PD. 2) To find out the severity of caregivers distress…Next-generation profiling to identify the molecular etiology of Parkinson’s disease dementia
Objective: To identify novel gene regulatory events associated with Parkinson's disease with dementia (PD-D). Background: PD-D is associated with the spread of degenerative pathology to…Heart rate variability to differentiate dementia with Lewy bodies from Alzheimer’s disease in patients with mild cognitive impairment
Objective: We aimed to determine whether heart rate variability (HRV) can aid in the differentiation of DLB from AD at the MCI stage. Background: Mild…Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson’s disease
Objective: To investigate the role of APOE, MAPT, COMT, SNCA and GBA genes in both striatal dopaminergic denervation and the development of dementia in Parkinson's…How accurate is the prediction of driving ability in a Parkinson’s clinic setting?
Objective: To determine whether routine clinical assessment (motor examination, cognitive assessment and global clinical impression) accurately predicts the ability of People with Parkinson's (PwP) to…A novel phenotype of amyloid precursor protein (APP) mutation presenting with dementia, and symptoms of both progressive supranulcear palsy (PSP) and multisystem atrophy (MSA)
Objective: To describe the novel phenotype of a patient with an amyloid precursur protein (APP) mutation presenting with dementia and symptoms of both progressive supranulcear…Comparison of Test Your Memory (TYM) and Montreal Cognitive Assessment (MoCA) measures in Parkinson’s disease
Objective: We sought to determine: a) the ability of TYM to discriminate between PD patients with and without cognitive deficits b) equivalence between MoCA scores…Neuro-cognitive domain related to conversion of Parkinson’s disease dementia
Objective: To identify neurocognitive domain and mild cognitive impairment (MCI) subtype associated with conversion from non-demented patients with Parkinson's disease (PD) and PD-MCI to dementia…Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia
Objective: To examine the clinical profile of nelotanserin, a novel agent in development for the treatment of Lewy body dementia. Background: Although not FDA-approved for…Survey of prodromal symptoms of Parkinson’s disease in Japan
Objective: To reveal prodromal symptoms at a public seminar for PD via questionnaires. Background: How to select subjects with PD for disease modify therapy in…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 36
- Next Page »